116 related articles for article (PubMed ID: 9364998)
1. Comment on: Bivalirudin during thrombolysis with catheter-directed tPA in a heparin-refractory patient: A case report.
Han JH
Pediatr Blood Cancer; 2024 Jun; 71(6):e30992. PubMed ID: 38556764
[No Abstract] [Full Text] [Related]
2. Low molecular weight protamine as nontoxic heparin/low molecular weight heparin antidote (III): preliminary in vivo evaluation of efficacy and toxicity using a canine model.
Lee LM; Chang LC; Wrobleski S; Wakefield TW; Yang VC
AAPS PharmSci; 2001; 3(3):E19. PubMed ID: 11741270
[TBL] [Abstract][Full Text] [Related]
3. Use of recombinant tissue plasminogen activator (rTPA) for treatment of fibrin in the anterior chamber of the horse.
Pereira R; Bowen M; Rapezzano G; Redpath A; Pratt S; Hallowell G
Vet Med Sci; 2024 Jul; 10(4):e1448. PubMed ID: 38818763
[TBL] [Abstract][Full Text] [Related]
4. Interaction between the LMWH reviparin and aspirin in healthy volunteers.
Klinkhardt U; Breddin HK; Esslinger HU; Haas S; Kalatzis A; Harder S
Br J Clin Pharmacol; 2000 Apr; 49(4):337-41. PubMed ID: 10759689
[TBL] [Abstract][Full Text] [Related]
5. Platelet Membrane-Coated r-SAK Improves Thrombolytic Efficacy by Targeting Thrombus.
Hua R; Li M; Lin Q; Dong M; Gong X; Lin Z; Li Y; Li C; Wu T; Tan C; Zhang W; Wang Q; Wu T; Zhou X; Yang F; Li C
ACS Appl Mater Interfaces; 2024 May; 16(17):21438-21449. PubMed ID: 38626407
[TBL] [Abstract][Full Text] [Related]
6. Comparison of edoxaban and enoxaparin in a rat model of AlCl
Hachenberger M; Yeniguen M; Suenner L; Hinchliffe D; Mueller C; Wietelmann A; Gerriets T; Tschernatsch M; Juenemann M; Gerner ST; Doeppner TR; Huttner HB; Braun T
Naunyn Schmiedebergs Arch Pharmacol; 2023 Dec; 396(12):3887-3892. PubMed ID: 37261475
[TBL] [Abstract][Full Text] [Related]
7. Unified Methodology for the Primary Preclinical In Vivo Screening of New Anticoagulant Pharmaceutical Agents from Hematophagous Organisms.
Kostromina MA; Tukhovskaya EA; Shaykhutdinova ER; Palikova YA; Palikov VA; Slashcheva GA; Ismailova AM; Kravchenko IN; Dyachenko IA; Zayats EA; Abramchik YA; Murashev AN; Esipov RS
Int J Mol Sci; 2024 Apr; 25(7):. PubMed ID: 38612796
[TBL] [Abstract][Full Text] [Related]
8. Controllable Thrombolysis Using a Nanobubble-Imaging-Guided rtPA Targeted Delivery Strategy.
Tang J; Xu H; Li M; Liu Y; Yang F
BME Front; 2024; 5():0040. PubMed ID: 38550853
[No Abstract] [Full Text] [Related]
9. 2022 Update of the Consensus on the Rational Use of Antithrombotics and Thrombolytics in Veterinary Critical Care (CURATIVE) Domain 6: Defining rational use of thrombolytics.
Sharp CR; Blais MC; Boyd CJ; Brainard BM; Chan DL; de Laforcade A; Goggs R; Guillaumin J; Lynch A; Mays E; McBride D; Rosati T; Rozanski EA
J Vet Emerg Crit Care (San Antonio); 2022 Jul; 32(4):446-470. PubMed ID: 35881647
[TBL] [Abstract][Full Text] [Related]
10. A novel hirudin derivative characterized with anti-platelet aggregations and thrombin inhibition.
Mo W; Zhang YL; Chen HS; Wang LS; Song HY
J Thromb Thrombolysis; 2009 Aug; 28(2):230-7. PubMed ID: 18998199
[TBL] [Abstract][Full Text] [Related]
11. Bivalirudin: a review of its potential place in the management of acute coronary syndromes.
Carswell CI; Plosker GL
Drugs; 2002; 62(5):841-70. PubMed ID: 11929334
[TBL] [Abstract][Full Text] [Related]
12. Does antithrombotic therapy influence residual thrombus after thrombolysis of platelet-rich thrombus? Effects of recombinant hirudin, heparin, or aspirin.
Mruk JS; Zoldhelyi P; Webster MW; Heras M; Grill DE; Holmes DR; Fuster V; Chesebro JH
Circulation; 1996 Feb; 93(4):792-9. PubMed ID: 8641009
[TBL] [Abstract][Full Text] [Related]
13. Comparison of desulfatohirudin (REVASC) and heparin as adjuncts to thrombolytic therapy with reteplase in a canine model of coronary thrombosis.
Martin U; Dörge L; Fischer S
Br J Pharmacol; 1996 May; 118(2):271-6. PubMed ID: 8735626
[TBL] [Abstract][Full Text] [Related]
14. [Unstable angina pectoris: coagulation disorder and its therapy].
Meyer BJ
Praxis (Bern 1994); 1995 Feb; 84(8):232-8. PubMed ID: 7886362
[TBL] [Abstract][Full Text] [Related]
15. Direct thrombin inhibitors as adjuncts to thrombolytic therapy.
French JK; White HD
Curr Cardiol Rep; 1999 Sep; 1(3):184-91. PubMed ID: 10980840
[TBL] [Abstract][Full Text] [Related]
16. Comparison of enoxaparin, hirulog, and heparin as adjunctive antithrombotic therapy during thrombolysis with rtPA in the stenosed canine coronary artery.
Leadley RJ; Kasiewski CJ; Bostwick JS; Bentley R; McVey MJ; White FJ; Perrone MH; Dunwiddie CT
Thromb Haemost; 1997 Oct; 78(4):1278-85. PubMed ID: 9364998
[TBL] [Abstract][Full Text] [Related]
17. Antithrombotic efficacy of a novel factor Xa inhibitor, FXV673, in a canine model of coronary artery thrombolysis.
Rebello SS; Bentley RG; Morgan SR; Kasiewski CJ; Chu V; Perrone MH; Leadley RJ
Br J Pharmacol; 2001 Aug; 133(7):1190-8. PubMed ID: 11487531
[TBL] [Abstract][Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
